Teleflex Incorporated (TFX) has been the subject of varied sentiments in recent news, raising questions about potential buying or selling decisions. The NYSE-listed stock received a “Moderate Buy” consensus recommendation and analysts' consensus price target of $263.14. Antimicrobial protection has taken a spotlight with the news of the Teleflex Center's conception. Share movements have included sales by US Bancorp DE, purchases by Russell Investments Group Ltd., Bessemer Group and increases in stakes by Mitsubishi UFJ Trust & Banking Corp. Predictions indicate potential decline in Q2 earnings. Major holdings in the company by Vanguard Group Inc. and accumulation of shares by Texas Permanent School Fund Corp indicate strong institutional interest. CEO compensation has been deemed justifiable. Teleflex's stock is set for a bullish trajectory in the estimation of Truist Financial, which raised its price target to $240.00. Upgrades from Piper Sandler also boost the stock’s image while acquisitions like Palette Life Sciences will boost the company's urology portfolio. Lastly, the stock has been marked as undervalued indicating a good investing opportunity.
Teleflex Incorporated TFX News Analytics from Tue, 29 Oct 2013 07:00:00 GMT to Sun, 28 Jul 2024 06:35:10 GMT -
Rating 4
- Innovation 2
- Information 7
- Rumor -3
